Synonym: (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester; 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt; 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid; (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester; AHU-377 calcium salt; AHU377 calcium salt
CAS Number: 1369773-39-6
Empirical Formula (Hill Notation): C24H28NO5 · 0.5Ca
Molecular Weight: 430.52
Linear Formula: C24H28NO5 · 0.5Ca
Product Type: Chemical
assay |
≥98% (HPLC) |
color |
white to beige |
form |
powder |
Quality Level |
100 |
solubility |
DMSO: 10 mg/mL, clear |
storage condition |
desiccated |
storage temp. |
−20°C |
Biochem/physiol Actions: |
Sacubitril (AHU377) is a prodrug inhibitor of the membrane metallo-endopeptidase neprilysin. Sacubitril forms half of the heart failure combination drug LCZ696, along with the angiotensin-receptor blocker Valsartan. Sacubitril (AHU377) is cojnverted by esterases into the active inhibitor LBQ657, which prevents neprilysin′s degradation of atrial and brain natriuretic peptide, two blood pressure lowering peptides. The AHU377 valsartan combination drug LCZ696 showed a reduction in the risk of cardiovascular death of 20% compared to the standard ACE inhibitor enalapril, and also a 21% drop in the risk of hospitalization. |
Packaging: |
5, 25 mg in glass bottle |
Symbol |
GHS06,GHS09 |
Signal word |
Danger |
Hazard statements |
H301 - H400 |
Precautionary statements |
P273 - P301 + P310 + P330 |
RIDADR |
UN2811 - class 6.1 - PG 3 - EHS - Toxic solids, organic, n.o.s., |
WGK Germany |
WGK 3 |
Flash Point(F) |
Not applicable |
Flash Point(C) |
Not applicable |
Purity |
≥98% (HPLC) |
Storage Temp. |
−20°C |
UNSPSC |
12352200 |